Vaccination for children with cancer and their parents
Study on Compliance, Safety and Effectivity of Vaccination for Children With Hematologic Malignancies or Solid Tumors and Their Parents
This study is testing how safe and effective vaccinations are for children with cancer and their parents, and whether they are willing to get vaccinated after their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | Children's Cancer Group, China Research network |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT03373656 on ClinicalTrials.gov |
What this trial studies
This study evaluates the compliance, safety, and effectiveness of vaccinations for children diagnosed with hematologic malignancies or solid tumors, as well as their parents. Given that these children often experience immune deficiencies due to their conditions and treatments, the study aims to assess their willingness to receive vaccinations after completing their therapies. Researchers will collect data on any adverse effects and measure antibody levels in the children to determine the effectiveness of the vaccinations. The findings will help inform vaccination programs tailored for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates include children aged 18 years or younger who have undergone chemotherapy, hematopoietic stem cell transplantation, or splenectomy and are in clinical remission.
Not a fit: Patients who have not achieved clinical remission, are critically ill, or have a history of certain immunosuppressive treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the vaccination strategies for children with cancer, potentially reducing their risk of infectious diseases.
How similar studies have performed: Other studies have shown promise in vaccination strategies for immunocompromised populations, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Children patients(≤18 years) who accepted chemotherapy, hematopoietic stem cell transplantation or splenectomy since our study started. 2. No history of hepatitis B and measles, do not suffer from other diseases that affect immune function and allergic diseases. Exclusion Criteria: 1. Children patients who did not reach clinical remission after treatment, critically ill or eventually died. 2. Patients who used monoclonal antibodies, especially anti-tumor necrosis factors. 3. Intermittent or low-dose chemotherapy or other immunosuppressive drugs users.
Where this trial is running
Shanghai, Shanghai
- Shanghai Children's Medical Center — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Yi-Jin Gao, MD — Shanghai Children's Medical Center
- Study coordinator: Yi-Jin Gao, MD
- Email: gaoyijin@scmc.com.cn
- Phone: 86-21-38626161
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.